Maze Therapeutics, Common Stock Performance
| MAZE Stock | 40.55 1.55 3.68% |
On a scale of 0 to 100, Maze Therapeutics, holds a performance score of 20. The company secures a Beta (Market Risk) of 1.65, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Maze Therapeutics, will likely underperform. Please check Maze Therapeutics,'s kurtosis, and the relationship between the downside variance and day median price , to make a quick decision on whether Maze Therapeutics,'s current price movements will revert.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Maze Therapeutics, Common are ranked lower than 20 (%) of all global equities and portfolios over the last 90 days. In spite of rather unsteady basic indicators, Maze Therapeutics, exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (3.68) | Five Day Return (4.21) | Year To Date Return 154.23 | Ten Year Return 154.23 | All Time Return 154.23 |
1 | Insider Trading | 10/06/2025 |
2 | Maze Achieves Shopify Premier Partner Status, Expanding Support for Enterprise Brands Ready to GetUnstuck | 10/09/2025 |
3 | Disposition of 28423 shares by Homcy Charles J of Maze Therapeutics, subject to Rule 16b-3 | 10/23/2025 |
4 | Maze Therapeutics Hits New 12-Month High - Should You Buy - MarketBeat | 10/29/2025 |
5 | Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week | 11/06/2025 |
6 | Evaluating Maze Therapeutics Is the Current Valuation Justified After Recent Volatility | 11/11/2025 |
7 | Acquisition by Homcy Charles J of 1489 shares of Maze Therapeutics, subject to Rule 16b-3 | 11/19/2025 |
8 | Maze Therapeutics Stock Price Up 8.4 percent - Should You Buy - MarketBeat | 11/20/2025 |
9 | Were Not Worried About Maze Therapeutics Cash Burn | 12/15/2025 |
| Begin Period Cash Flow | 30.2 M | |
| Total Cashflows From Investing Activities | -1.1 M |
Maze Therapeutics, Relative Risk vs. Return Landscape
If you would invest 2,593 in Maze Therapeutics, Common on September 30, 2025 and sell it today you would earn a total of 1,617 from holding Maze Therapeutics, Common or generate 62.36% return on investment over 90 days. Maze Therapeutics, Common is currently generating 0.823% in daily expected returns and assumes 3.238% risk (volatility on return distribution) over the 90 days horizon. In different words, 29% of stocks are less volatile than Maze, and 84% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Maze Therapeutics, Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Maze Therapeutics,'s investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Maze Therapeutics, Common, and traders can use it to determine the average amount a Maze Therapeutics,'s price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2542
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | MAZE | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Maze Therapeutics, is performing at about 20% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Maze Therapeutics, by adding it to a well-diversified portfolio.
Maze Therapeutics, Fundamentals Growth
Maze Stock prices reflect investors' perceptions of the future prospects and financial health of Maze Therapeutics,, and Maze Therapeutics, fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Maze Stock performance.
| Return On Equity | -0.53 | ||||
| Return On Asset | -0.27 | ||||
| Current Valuation | 1.67 B | ||||
| Shares Outstanding | 48.12 M | ||||
| Price To Book | 5.34 X | ||||
| Price To Sales | 3.14 X | ||||
| Revenue | 167.5 M | ||||
| EBITDA | 60.88 M | ||||
| Net Income | 52.23 M | ||||
| Total Debt | 26.63 M | ||||
| Book Value Per Share | 7.89 X | ||||
| Cash Flow From Operations | 75.95 M | ||||
| Earnings Per Share | (2.56) X | ||||
| Market Capitalization | 2.03 B | ||||
| Total Asset | 240.54 M | ||||
| Retained Earnings | (358.43 M) | ||||
| Working Capital | 181 M | ||||
About Maze Therapeutics, Performance
By analyzing Maze Therapeutics,'s fundamental ratios, stakeholders can gain valuable insights into Maze Therapeutics,'s financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Maze Therapeutics, has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Maze Therapeutics, has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.22 | 0.23 | |
| Return On Capital Employed | 0.26 | 0.28 | |
| Return On Assets | 0.22 | 0.23 | |
| Return On Equity | 0.27 | 0.28 |
Things to note about Maze Therapeutics, Common performance evaluation
Checking the ongoing alerts about Maze Therapeutics, for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Maze Therapeutics, Common help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Maze Therapeutics, appears to be risky and price may revert if volatility continues | |
| Over 86.0% of the company shares are owned by institutional investors | |
| Latest headline from simplywall.st: Were Not Worried About Maze Therapeutics Cash Burn |
- Analyzing Maze Therapeutics,'s financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Maze Therapeutics,'s stock is overvalued or undervalued compared to its peers.
- Examining Maze Therapeutics,'s industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Maze Therapeutics,'s management team can have a significant impact on its success or failure. Reviewing the track record and experience of Maze Therapeutics,'s management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Maze Therapeutics,'s stock. These opinions can provide insight into Maze Therapeutics,'s potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Maze Stock analysis
When running Maze Therapeutics,'s price analysis, check to measure Maze Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Maze Therapeutics, is operating at the current time. Most of Maze Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Maze Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Maze Therapeutics,'s price. Additionally, you may evaluate how the addition of Maze Therapeutics, to your portfolios can decrease your overall portfolio volatility.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |